Figure 6.

MK2206 inhibits tumour growth in a mouse model of ILC. (a) Mouse ILC cells (mILC-1) were allowed to form primary tumours in recipient nude mice, and treatment with MK2206 (120 mg/kg) was commenced when mammary tumours reached an average volume of 100 mm³ (n = 13). Sham-treated animals (n = 13) were used as control. Preclinical intervention was continued for three weeks (denoted by red line), after which the experiment was ended. ^*P < 0.005. (b) Owing to the allosteric nature of the MK2206 inhibitor, inhibition of Akt signals in primary tumours was probed using immunohistochemical analysis of phosphorylated mTOR, a key downstream PI3K/Akt effector (lower panels). Note the inhibition of ILC growth (a) and phospho-mTOR (b) upon MK2206 treatment. H&E, haematoxylin and eosin staining. Sham, 30% captisol. Scale bars, 50 µm.